Department of Internal Medicine, Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan 48202, USA.
J Hypertens. 2011 Feb;29(2):330-8. doi: 10.1097/HJH.0b013e32834103ee.
Hypertension-induced renal injury is characterized by inflammation, fibrosis and proteinuria. Previous studies have demonstrated that N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) inhibits renal damage following diabetes mellitus and antiglomerular basement membrane nephritis. However, its effects on low-renin hypertensive nephropathy are not known. Thus, we hypothesized that Ac-SDKP has renal protective effects on deoxycorticosterone acetate (DOCA)-salt hypertensive mice, decreasing inflammatory cell infiltration, matrix deposition and albuminuria.
We uninephrectomized 16-week-old C57BL/6J mice and treated them with either placebo, DCOA (10 mg/10 g body weight subcutaneous) and 1% sodium chloride with 0.2% potassium chloride in drinking water (DOCA-salt) or DOCA-salt with Ac-SDKP (800 μg/kg per day) for 12 weeks. We measured blood pressure, urine albumin, glomerular matrix, renal collagen content, monocyte/macrophage infiltration and glomerular nephrin expression.
Treatment with DOCA-salt significantly increased blood pressure (P < 0.01), which remained unaltered by Ac-SDKP. Ac-SDKP decreased DOCA-salt-induced renal collagen deposition, glomerular matrix expansion and monocyte/macrophage infiltration. Moreover, DOCA-salt-induced increase in albuminuria was normalized by Ac-SDKP (controls, 10.8 ± 1.7; DOCA-salt, 41 ± 5; DOCA-salt + Ac-SDKP, 13 ± 3 μg/10 g body weight per 24 h; P < 0.001, DOCA-salt vs. DOCA-salt + Ac-SDKP). Loss of nephrin reportedly causes excess urinary protein excretion; therefore, we determined whether Ac-SDKP inhibits proteinuria by restoring nephrin expression in the glomerulus of hypertensive mice. DOCA-salt significantly downregulated glomerular nephrin expression (controls, 37 ± 8; DOCA-salt, 10 ± 1.5% of glomerular area; P < 0.01), which was partially reversed by Ac-SDKP (23 ± 4.0% of glomerular area; P = 0.065, DOCA-salt vs. DOCA-salt + Ac-SDKP).
We concluded that Ac-SDKP prevents hypertension-induced inflammatory cell infiltration, collagen deposition, nephrin downregulation and albuminuria, which could lead to renoprotection in hypertensive mice.
高血压引起的肾损伤的特征是炎症、纤维化和蛋白尿。先前的研究表明,N-乙酰-Ser-Asp-Lys-Pro(Ac-SDKP)可抑制糖尿病和抗肾小球基底膜肾炎后的肾损伤。然而,其对低肾素性高血压肾病的作用尚不清楚。因此,我们假设 Ac-SDKP 对去氧皮质酮醋酸盐(DOCA)-盐性高血压小鼠具有肾脏保护作用,可减少炎症细胞浸润、基质沉积和白蛋白尿。
我们对 16 周龄的 C57BL/6J 小鼠进行单侧肾切除术,并用安慰剂、DOCA(10mg/10g 体重皮下)和 1%氯化钠加 0.2%氯化钾饮用水(DOCA-盐)或 DOCA-盐加 Ac-SDKP(800μg/kg/天)治疗 12 周。我们测量血压、尿白蛋白、肾小球基质、肾胶原含量、单核细胞/巨噬细胞浸润和肾小球足细胞蛋白表达。
DOCA-盐治疗显著增加了血压(P<0.01),而 Ac-SDKP 治疗则未改变血压。Ac-SDKP 降低了 DOCA-盐诱导的肾胶原沉积、肾小球基质扩张和单核细胞/巨噬细胞浸润。此外,Ac-SDKP 使 DOCA-盐诱导的白蛋白尿增加正常化(对照组,10.8±1.7;DOCA-盐,41±5;DOCA-盐+Ac-SDKP,13±3μg/10g 体重/24h;P<0.001,DOCA-盐 vs. DOCA-盐+Ac-SDKP)。足细胞蛋白丢失据报道会导致尿蛋白排泄过多;因此,我们确定 Ac-SDKP 是否通过恢复高血压小鼠肾小球中的足细胞蛋白表达来抑制蛋白尿。DOCA-盐显著下调肾小球足细胞蛋白表达(对照组,37±8;DOCA-盐,肾小球面积的 10±1.5%;P<0.01),而 Ac-SDKP 部分逆转了这一下调(肾小球面积的 23±4.0%;P=0.065,DOCA-盐 vs. DOCA-盐+Ac-SDKP)。
我们得出结论,Ac-SDKP 可预防高血压引起的炎症细胞浸润、胶原沉积、足细胞蛋白下调和白蛋白尿,从而在高血压小鼠中实现肾脏保护。